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Abstract
Background: MicroRNA-126 is the only microRNA (miRNA) known to be endothelial cell-specific influencing
angiogenesis in several ways. The aim of the present study was to analyse the possible predictive value of
miRNA-126 in relation to first line capecitabine and oxaliplatin (XELOX) in patients with metastatic colorectal cancer
(mCRC).
Methods: The study included 89 patients with mCRC. In situ hybridization (ISH) was performed to detect
miRNA-126 in formalin-fixed paraffin embedded tissue from primary tumours. The expression of miRNA-126, area
per image (μm2), was measured using image analysis. Clinical response was evaluated according to RECIST.
Progression free survival (PFS) was compared using the Kaplan-Meier method and the log rank test. Tumours were
classified as low or high miRNA-126 expressing tumours using the median value from the patients with response
as cut-off.
Results: The median miRNA-126 expression level was significantly higher in patients responding to XELOX, 3629
μm2 (95% CI, 2566-4846), compared to the patients not responding, 1670 μm2 (95% CI, 1436-2041), p < 0.0001. The
positive predictive value was 90%, and the negative predictive value was 71%. The median PFS of patients with
high expressing tumours was 11.5 months (95% CI, 9.0-12.7 months) compared to 6.0 months (95% CI, 4.8-6.9
months) for patients with low expressing tumours, p < 0.0001.
Conclusions: Angiogenesis quantified by ISH of miRNA-126 was related to response to first line XELOX in patients
with mCRC, translating to a significant difference in PFS. The predictive value of miRNA-126 remains to be further
elucidated in prospective studies.
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Background
In the recent years, a rapidly growing number of treat-
ment modalities have become available for the treatment
of patients with metastatic colorectal cancer (mCRC). It
is therefore more important than ever to identify the
right patients for the right treatment. Combination che-
motherapy constitutes the backbone of mCRC treatment
and combined with anti-angiogenetic therapy this is a
common first line choice.
In the search for potential biomarkers, angiogenesis,
the formation of new blood vessels from pre-existing
vessels, has been addressed for obvious reasons, includ-
ing the introduction of anti-angiogenetic treatment.
Furthermore, the important role of angiogenesis in the
growth and dissemination of malignant tumours [1-3]
argues for testing biomarkers related to the neo-
formation of the vasculature in malignancies.
MicroRNAs (miRNAs) are a group of small, non-
coding RNAs that regulate several biological functions,
and increasing evidence supports a pivotal role in the
regulation of pathological processes as well [4,5]. The
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number of reports on miRNAs and their involvement
in CRC pathogenesis is rapidly growing [6] and a rela-
tionship between miRNA expression patterns and
response to cytotoxic treatment has also been demon-
strated [7-10]. MicroRNA-126 [GenBank: NR_029695]
is so far the only identified endothelial cell (EC)-speci-
fic miRNA [11] and its important role in regulating
angiogenesis has been demonstrated in a few studies
[12-14]. High levels of miRNA-126 expression have
been correlated with increased vascular endothelial
growth factor A (VEGF-A) mediated signalling in ECs
and a higher blood vessel integrity [12,14,15]. Thus,
current evidence seems to support a close relationship
between miRNA-126 and physiological angiogenesis,
but the mechanism of the regulation under different
normal and malignant conditions remains to be eluci-
dated. MicroRNA-126 is often referred to as a tumour
suppressor in primary tumours and cancer cell lines
[16-20]. Thus, inhibition of cancer cell-growth has
been demonstrated after restoration of miRNA-126
levels [17,19,21]. Based on the current knowledge
about angiogenesis, blood vessel structure, interstitial
tumour pressure and their influence on the delivery of
chemotherapy to the tumour cells [22-25], one could
hypothesise that miRNA-126 would likewise harbour
predictive information.
The aim of this study was to analyse the possible pre-
dictive value of miRNA-126 in patients with mCRC in
relation to first line treatment with capecitabine and
oxaliplatin (XELOX).
Methods
Study population, sampling and treatment regimen
The study included 89 patients with mCRC histologi-
cally verified at the Department of Clinical Pathology,
Vejle Hospital, Denmark (Table 1). First line chemother-
apy was initiated in the period from May 2004 to
December 2009. Pre-treatment examination consisted of
standard hematologic parameters and a CT scan of the
chest and abdomen or a chest x-ray and ultrasound of
the abdomen. All patients received a minimum of 3
cycles of XELOX. Formalin fixed paraffin embedded
(FFPE) tumour tissue originating from the primary
tumour was available from all patients. Patients having
received preoperative chemoradiation of rectal cancer
were not included. All patients meeting these criteria
were offered inclusion in the study.
Two patients had a previous diagnosis of breast can-
cer, but had no sign of relapse at the time of diagnosis
of their CRC, and their survival data were consequently
left uncensored. No patients were diagnosed with a new
malignancy after their CRC diagnosis. Progression free
survival data were censored in 10 cases. Six patients
initiated a second-line treatment before progression and
data were censored from the first day of their new treat-
ment. Two patients underwent radio frequency ablation,
and two patients had surgical resection of their liver
metastases and their data were censored from the day of
the intervention.
Immediately after surgery the removed bowel segment
was brought to the Department of Clinical Pathology
and a pathologist sampled tissue from the tumour. Sam-
ples intended for later in situ hybridization (ISH) ana-
lyses followed routine fixation and paraffin embedding.
Postoperatively, the tumours were histologically classi-
fied and staged according to the pTNM system. Infor-
mation regarding patient characteristics, relapse status
and survival were based on patient records, pathology
reports, and a national registry based on central person
registration numbers.
All patients received the same treatment (XELOX),
which consisted of a 2-hour intravenous infusion of oxa-
liplatin 130 mg/m2 on day 1 followed by oral capecita-
bine 1000 mg/m2 twice daily on days 1 through 14 (28
Table 1 Patient characteristics at time of diagnosis
Number (%) miRNA-126 expression level
(μm2)
(n = 89) Median (95% CI) p - value
Sex
Male 45 (51) 2533 (1690-3285) 0.84
Female 44 (49) 2354 (1650-3163)
Age (years)
Mean (SD) 63.2 (8.2)
Range 24 - 80
> mean 49 (55) 2088 (1556-3223) 0.56
< mean 40 (45) 2531 (1896-3355)
ECOG Performance status
0 37 (42) 2041 (1551-3163) 0.40
1-2 52 (58) 2535 (1708-3489)
Localization
Rectum 18 (20) 3038 (1690-4030) 0.37
Colon 71 (80) 2141 (1650-2638)
Left colon 47 (66) 2141 (1589-2818) 0.99
Right colon 24 (34) 2232 (1452-3355)
MSI status*
MSI 8 (11) 2193 (1374-5421) 0.61
MSS 62 (89) 2355 (1705-2818)
Metastatic sites*
1 27 (31) 3575 (3163-4521) < 0.0001
≥ 2 59 (69) 1857 (151-2376)
CI confidence interval, SD standard deviation, ECOG Eastern Cooperative
Oncology Group, MSI microsatellite instability, MSS , microsatellite stable
*MSI status was not assessed in all patients
**A reliable estimate of the number of metastatic sites was not possible in 3
patients
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doses) of a 21-days cycle. Treatment was continued until
disease progression or unacceptable toxicity.
The study was approved by the Regional Scientific
Ethical Committee for Southern Denmark according to
Danish law, J.nr. S-VF-20040047, and informed consent
was obtained from all patients enrolled in the study.
Evaluation and tumour response criteria
Treatment response, according to RECIST (version 1.0),
was assessed every 9 weeks with clinical and radiologic
examination using CT scan of the chest and abdomen
(86 patients) or a chest x-ray and ultrasound of the
abdomen (3 patients). Responding patients were classi-
fied as having either complete response (CR) or partial
response (PR). Patients with stable disease (SD) or pro-
gressive disease (PD) were defined as non-responders.
All CT scans were evaluated by the same investigator
(TFH).
LNA probe, in situ hybridization, image analysis and
quantification
The entire ISH procedure and the subsequent quantifi-
cation was performed at Exiqon, Vedbaek, Denmark and
followed previously described procedures [26,27].
In brief, the ISH analysis was carried out on 6-μm
thick FFPE tissue sections containing CRC tissue, using
a double digoxigenin (DIG)-labelled mercury Locked
Nucleic Acid (LNA) probe (LNA™ microRNA detection
probe, Exiqon, Vedbaek, Denmark) specific for human
miRNA-126. Tissue sectioning was performed in an
RNase-free environment.
An initial assay optimization was performed on nine
sections from five CRC samples in order to determine
the optimal probe concentration and hybridization tem-
perature. The ISH assay involved a protein-K treatment
(15 μg/ml) followed by a hybridization step, using the
LNA probe at 57°C and stringent washes. The DIG-
labelled probe was detected with alkaline phosphatase
conjugated sheep anti-DIG Fab fragments followed by
NBT-BCIP chromogenic staining and nuclear fast red
staining.
For image acquisition up to 25 random, systematically
positioned images were collected from the tumour slide.
Initially, the whole tumour area was encircled to avoid
ulcerating, necrotic and normal tissue. Images contain-
ing distorted tissue and staining artefacts were deleted
and only images with cancer cells and tumour stroma
were included. A corresponding pixel classifier included
the following colours for the identification of the stained
histological structures. Intense blue (the ISH signal),
weak blue (background ISH signal), red (nuclear stain),
red spot (mucin), black spot (artefact), unstained (no-tis-
sue and erythrocytes). The area of the ISH signal (μm2
per image), was used as the parameter reflecting
miRNA-126 expression levels, and the mean score from
the sampled images (at × 20 magnification) was used for
each patient. Figure 1 provides examples of the underly-
ing pixel classifier. The entire ISH procedure was per-
formed by a staff unaware of the clinical parameters.
Statistical analysis
Fisher’s exact test was used for two-group comparisons.
Median values were compared using the Wilcoxon rank
sum test. Progression free survival (PFS) was defined as
the time from start of treatment until the first docu-
mented tumour progression or death. Overall survival
(OS) was defined as the time from start of treatment
until death. All survival data were complete. Survival
curves were illustrated according to the Kaplan-Meier
method and the logrank test was used to test for differ-
ences between the groups. All statistical calculations
were carried out using the NCSS statistical software
(NCSS Statistical Software, Kaysville, UT 84037, USA,
version 2007). P values < 0.05 were considered signifi-
cant, and all tests were two-sided.
Results
The miRNA-126 ISH resulted in a strong signal in var-
ious vessels throughout the tumour in all the samples
(Figure 1). No apparent unspecific signals were detected
from the extracellular matrix, but background signal
was detected in a few samples caused by tumour sec-
tions being too thick.
Patient characteristics
The patient characteristics along with the miRNA-126
expression levels in the primary tumours are shown in
Table 1. A significant relationship was demonstrated
between the number of metastatic sites and the median
miRNA-126 expression level. The presence of two or
more metastatic sites was related to lower miRNA-126
expression levels compared to the expression levels in
patients with metastases limited to one site.
The predictive value of miRNA-126 in relation to XELOX
Eighty-three patients were included in the analyses of
the predictive value of miRNA-126 in relation to first
line XELOX in mCRC. Five patients were excluded due
to the fact that XELOX was given as second or third
line treatment, and one patient was excluded because of
insufficient response evaluation according to the
RECIST criteria.
The distribution of miRNA-126 expression levels
according to response is shown in Figure 2. The med-
ian miRNA expression level was significantly higher in
the responding patients, 3629 (95% CI 2566-4846)
compared to the non-responding patients, 1670 (95%
CI 1436-2041), p = 5 × 10-6. The largest difference in
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Figure 1 In situ hybridization (ISH) visualising the expression of miRNA-126 in tumour vasculature. A represents an image from a patient
with colon cancer in which the mean ISH signal (the blue signal) from all the analysed images resulted in an area of 4280 μm2. B the pixel
classifier corresponding to image A. C also represents an image from a patient with colon cancer with a mean ISH signal of 2736 μm2. D the
pixel classifier corresponding to image C.
Figure 2 Relationship between miRNA-126 and response. (A) Distribution of miRNA-126 expression levels according to response or non-
response to first line XELOX in patients with mCRC, black bars represent the medians, n = 83. The difference between the medians in the two
groups was significant, p = 0.000005. (B) Illustration of the same distribution divided into the four response groups (PD; progressive disease, SD;
stable disease, PR; partial response and CR; complete response). A significant difference between the median miRNA-126 expression levels in the
patients achieving SD compared to PR was observed, p = 0.001. The miRNA-126 expression levels from five patients (outliers, levels ranging from
16775-40284) are not shown in the figures for graphical reasons only, but were included in the statistics. Two of these patients achieved PR and
the remaining three CR.
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median miRNA-126 expression levels was demon-
strated when comparing patients achieving SD to
patients achieving PR.
In order to assess the predictive value of the miRNA-
126 ISH analysis in the context of predicting response
to first line XELOX treatment, patients were divided
into two groups. The median value (3629 μm2) from the
response group was used as cut-off. Applying this strat-
egy, the predictive value of a positive test ( > 3629 μm2)
was 19/21 = 90%, and of a negative test ( < 3629 μm2)
was 44/62 = 71%.
The same division of the patients was used in the sub-
sequent PFS analysis (Figure 3A). The difference in
response rates between the two groups reflected a signif-
icant difference in PFS, p < 0.0001. The median PFS for
patients with high miRNA-126 expression levels was
11.5 months (95% CI 9.0-12.7 months) compared to 6.0
months (95% CI 4.8-6.9 months) for patients with low
expression levels. The difference in PFS translated into a
significant difference in OS as well, p = 0.0021 (Figure
3B). The median OS in the group with high miRNA-126
expression was 26.2 months (95% CI 21.8-32.8 months)
compared to 16.8 months (95% CI 13.8-19.1 months) in
the group with low miRNA-126 expression.
The median overall survival for the entire cohort was
18.5 months (95% CI 16.7-21.8 months).
A subgroup analysis comparing patients with colon
cancer and rectum cancer did not change any of the
presented results.
Discussion
An increasing number of pre-clinical studies have
demonstrated a pivotal role of miRA-126 in regulating
angiogenesis, a process that has also been related to the
delivery and the efficacy of chemotherapy. Little is
known, though, about the in vivo localisation of
miRNA-126 in human CRC tissue samples, but the
present results support the previous studies indicating
specificity towards ECs. In the present study we ana-
lysed the possible predictive value of miRNA-126 in
relation to first line XELOX therapy in patients with
mCRC, using a quantitative analysis of the miRNA-126
expression level based on ISH analyses of tumour sec-
tions from the primary tumour. This method has
recently demonstrated its reliability in predicting short
disease-free survival in stage II colon cancer patients
[26].
A significant relationship between miRNA-126 expres-
sion levels and number of metastatic sites was demon-
strated. The miRNA-126 expression level was
significantly lower in patients with two or more meta-
static sites compared to the patients with disease limited
to only one metastatic location. This could indicate that
the molecular genetic features of the tumour cells origi-
nating from the primary tumours with low levels of
miRNA-126 are related to the ease by which these cir-
culating tumour cells invade tissues and gives rise to
distant metastases. This seems to apply rather well with
the conception of miRNA-126 functioning as a tumour
suppressor.
In the present study a significant relationship between
miRNA-126 expression levels in the primary tumour
and response to first line XELOX treatment was demon-
strated for patients with mCRC. Previous studies have
also reported on predictive value of markers related to
angiogenesis in patients with mCRC [28,29]. The pre-
sent marker, miRNA-126, is related to vessel integrity
[15], and correlations between vessel structure and
response to chemotherapy have previously been demon-
strated [24,25] supporting the plausibility of the present
results. Furthermore, a study by Zhou et al. [9] reported
on changes of miRNA expression profiles in colon can-
cer cell lines following exposure to XELOX. Low expres-
sion levels of miRNA-126 may therefore represent
Figure 3 Kaplan-Meier survival curves according to miRNA-126 expression levels. (A) Illustrates the progression free survival (PFS) curves
and (B) the overall survival (OS) curves. The yellow lines represent patients with high miRNA-126 expression levels and the blue lines patients
with low miRNA-126 expression. The difference between the curves was significant in the PFS comparison, p < 0.0001, as well as in the OS
comparison, p = 0.0021.
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tumour vessels with lower integrity and the expected
increase in the interstitial tumour pressure that follows
may explain the lower response rates seen in these
patients.
Dividing the patients by cut-off method, i.e. median
miRNA-126 expression level, demonstrated that the
observed relationship with response rates was also trans-
lated into a corresponding difference in PFS. A differ-
ence in OS was also demonstrated, when comparing
patients with low and high miRNA-126 expression
levels. The relationship with OS may indicate that
miRNA-126 has a prognostic importance in addition to
the predictive value. We did not find it indicated to per-
form a multivariate survival analysis adjusting for para-
meters of prognostic importance in stage I through III
disease in this cohort of patients with stage IV disease.
In the study by Díaz et al. no prognostic value of
miRNA-126 was demonstrated in patients with stage I
to III colon cancer [30]. The disease stage of the
included patients constitutes one of the major differ-
ences between their study and ours, which included
patients with stage IV disease only. Schepeler et al.
showed that miRNA-126 was up-regulated in patients
with subsequent recurrence compared to patients with
no recurrence in a cohort of 37 patients operated for
stage II colon cancer with microsatellite stable tumours
only [31]. Differences in methods, sample size, and stage
of the disease again represent the most obvious explana-
tions of these discrepancies, but the results from the
three studies indicate that the possible prognostic value
of miRNA-126 remains to be further clarified. If indeed,
assessment of miRNA-126 expression in the primary
tumour from patients with CRC harbours prognostic
value, one would expect a better prognosis for patients
with higher expression levels of this miRNA if function-
ing as a tumour suppressor.
The present study has the standard limitations of a
retrospective study; a rather limited sample size and
results obtained form a single institution. Having said
that it also represents a well argued hypothesis, a reli-
able method, and results of clinical relevance in line
with the preclinical literature.
An alternative technique to quantify angiogenesis is
presented based on ISH of miRNA-126 in primary
tumour tissue and using a specific LNA based probe
and new quantitative systematic image analyses. This
approach resulted in an estimate related to disease char-
acteristics, the response to chemotherapy, and the prog-
nosis of patients with mCRC. The new application of
the ISH method presented here indicated that miRNA-
126 may be an important predictive marker to che-
motherapy applied in the clinical setting, but the results
call for validation in a prospective trial. Furthermore, it
shall be interesting to analyse the possible predictive
value of miRNA-126 in patients with mCRC treated
with chemotherapy combined with anti-VEGF-A.
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